Skip to main content

Advertisement

SpringerLink
Log in

Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

miRNAs are small RNAs and control the expression of protein-encoding genes. The aim of this study was to determine the association between miRNA profile and clinical variables including age, stage, B symptom, histopathologic subtype, response to treatment, disease-free survival (DFS) and overall survival (OS) in classical Hodgkin lymphoma (cHL). A total of 377 miRNAs were studied by qPCR in 32 cases with cHL, and results were compared with 60 samples taken from cases with reactive lymphadenopathy. Biogazelle qbasePLUS 2.0 software was used to analyze the results. miR-582-3p, miR-525-3p, miR-448, miR-512-3p, miR-642a-5p, miR-876-5p, miR-532-3p, miR-654-5p, miR-128, miR-145-5p, miR-15b-5p, miR-328 and miR-660-5p were found to be decreased in cHL compared with controls. In contrast, miR-34a-5p (2.626-fold), miR-146a-5p (4.32-fold), miR-93-5p (2.347-fold), miR-20a-5p (4.930-fold), miR-339-3p (4.948-fold), miR-324-3p (4.98-fold), miR-372 (7.038-fold), miR-127-3p (8.234-fold), miR-155-5p (4.947-fold), miR-320a (17.502-fold) and miR-370 (21.479-fold) (p < 0.05) were found to be increased in cHL. There was no difference in miRNA profile according to the age, sex, stage, response to treatment, DFS and OS. However, miR-889 was found to be increased in patients with B symptom and miR-127-3p was found to be increased in nodular sclerosing subtype. Some miRNAs increase and some decrease in cHL. However, there was no clinical association between clinical variables and with the majority of the miRNA profile studied in this study. miR-889 and miR-127-3p were related to B symptom and nodular sclerosis subtype, respectively. We need more studies evaluating miRNA profile and clinical outcome in Hodgkin Lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Healy NA, Heneghan NA, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic miRNAs as potential biomarkers for malignancy. Int J Cancer. 2012;131:2215–22.

    Article  CAS  PubMed  Google Scholar 

  2. Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160:571–81.

    Article  CAS  PubMed  Google Scholar 

  3. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.

    Article  CAS  PubMed  Google Scholar 

  5. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Song G, Gu L, Li J, Tang Z, Liu H, Chen B, Sun X, He B, Pan Y, Wang S, Cho WC. Serum microRNA expression profiling predict response to RCHOP treatment indiffuse large B cell lymphoma patients. Ann Hematol. 2014;93:1735–43.

    Article  CAS  PubMed  Google Scholar 

  7. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.

    Article  CAS  PubMed  Google Scholar 

  8. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499–505.

    Article  PubMed  Google Scholar 

  9. Ansell Stephen M. Hodgkin lymphoma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:772–9.

    Article  Google Scholar 

  10. Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Möller P, Poppema S, Kroesen BJ, van den Berg A. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia. 2009;11:167–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207:243–9.

    Article  CAS  PubMed  Google Scholar 

  12. Van Vlierberghe P, De Weer A, Mestdagh P, Feys T, De Preter K, De Paepe P, Lambein K, Vandesompele J, Van Roy N, Verhasselt B, Poppe B, Speleman F. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. Br J Haematol. 2009;147:686–90.

    Article  PubMed  Google Scholar 

  13. Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LHC, Chadburn A, Tuschl T, Knowles DM, Tam W. MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol. 2008;173:242–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E, Monzo M. Regulation of JAK2 bymiR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009;114:2945–51.

    Article  CAS  PubMed  Google Scholar 

  15. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alves FJ, Canales M, Estevez M, Menarguez J, Sabin P, Ruiz-Marcellan MC, Lopez A, Sanchez-Godoy P, Burgos F, Santonja C, Lopez J, Piris MA, Garcia JF. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol. 2013;162:336–47.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study has been supported by Turkish Society of Hematology.

Author contributions

Semra Paydas contributed to study design, clinical management of the patients, paper writing and last control. Arbil Acikalin-Melek Ergin contributed to histopathologic examinations and re-evaluations of the biopsy samples; Hikmet Celik-Basak Yavuz did PCR analyses; Kahraman Tanriverdi contributed to coordination of all laboratory studies and statistical analyses.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Faculty of Medicine, Cukurova University, Balcali, Adana, Turkey

    Semra Paydas

  2. Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey

    Arbil Acikalin & Melek Ergin

  3. TorosGen Biotechnology, Technoscope, Mersin University, Mersin, Turkey

    Hikmet Celik & Basak Yavuz

  4. Department of Biochemistry, Massachusetts General Hospital, Boston, MA, USA

    Kahraman Tanriverdi

Authors
  1. Semra Paydas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arbil Acikalin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melek Ergin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hikmet Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Basak Yavuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kahraman Tanriverdi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Semra Paydas.

Ethics declarations

Conflict of interest

There is no conflict of interest.

Ethical standard

This study has been approved by the ethics committee.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paydas, S., Acikalin, A., Ergin, M. et al. Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables. Med Oncol 33, 34 (2016). https://doi.org/10.1007/s12032-016-0749-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0749-5

Keywords

Search

Navigation